Important note: Information in this article was accurate in November 2003. The state of the art may have changed since the publication date.
 |
HIV Treatment Bulletin - November 2003
Simon Collins, HIV i-Base
Indinavir levels were also significantly reduced when coadministered with the proton-pump inhibitor omeprazole.1 It is generally thought that this would not cause a clinically significant interaction.2
The study randomised volunteers to either placebo or 20mg, 40mg of omeprazole for seven days and on day seven added either indinavir 800mg alone or boosted with 200mg ritonavir.
Indinavir 24-hour AUC decreased by almost half from 30.0 mg/hr/mL to 16 mg/hr/mL and 12-hour Cmin decreased 55% from 82.3 ng/mL to 37.0 ng/mL.
Comment
This is another interaction that it is important to be aware of. It is not clear why 12-hour Cmin was measured for unboosted indinavir which is prescribed on TID basis or why the choice of boosted dose of 200mg ritonavir was chosen as this is higher than most patients use due to increased side effects.
References
1. Rublein JC, Donovan BJ, Hollowell SB et al. Effect of omeprazole on the plasma concentrations of indinavir in HIV-negative subjects. 43rd ICAAC, September, 2003; Abstract A-1611.
2. University of Liverpool drug interaction charts.
http://www.hiv-druginteractions.org/
031110
IB30409-09
©2003. I-BASE HIV Treatment Bulletin. Permission to reproduce courtesy of HIV i-Base, Third Floor East, Thrale House, 44-46 Southwark Street, London SE1 1UN - T: +44 (0) 20 7407 8488 F: +44 (0) 20 7407 8489
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted grants from Boehringer Ingelheim, Elton John AIDS Foundation, iMetrikus, Inc., John M. Lloyd Foundation, the National Library of Medicine, and donations from users like you. Always watch for outdated information. This article first appeared in 2003. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 2003. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content.
